JP2023535034A5 - - Google Patents
Info
- Publication number
- JP2023535034A5 JP2023535034A5 JP2023504346A JP2023504346A JP2023535034A5 JP 2023535034 A5 JP2023535034 A5 JP 2023535034A5 JP 2023504346 A JP2023504346 A JP 2023504346A JP 2023504346 A JP2023504346 A JP 2023504346A JP 2023535034 A5 JP2023535034 A5 JP 2023535034A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- day
- total dose
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| US63/055,362 | 2020-07-23 | ||
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535034A JP2023535034A (ja) | 2023-08-15 |
| JP2023535034A5 true JP2023535034A5 (https=) | 2024-07-24 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504346A Pending JP2023535034A (ja) | 2020-07-23 | 2021-07-23 | ５－メチル－１，２，４－オキサジアゾール－３－イル化合物の低用量レジメン及び製剤化 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (https=) |
| EP (1) | EP4185291B1 (https=) |
| JP (1) | JP2023535034A (https=) |
| KR (1) | KR20230043905A (https=) |
| CN (1) | CN116323604A (https=) |
| AR (1) | AR123031A1 (https=) |
| AU (1) | AU2021312894B2 (https=) |
| BR (1) | BR112023000975A2 (https=) |
| CA (1) | CA3186808A1 (https=) |
| CL (1) | CL2023000194A1 (https=) |
| CO (1) | CO2023000594A2 (https=) |
| DO (1) | DOP2023000009A (https=) |
| EC (1) | ECSP23005057A (https=) |
| ES (1) | ES3039536T3 (https=) |
| IL (1) | IL300023A (https=) |
| JO (1) | JOP20230018A1 (https=) |
| MX (1) | MX2023000993A (https=) |
| PE (1) | PE20231031A1 (https=) |
| PH (1) | PH12023550177A1 (https=) |
| TW (1) | TW202220650A (https=) |
| WO (1) | WO2022020663A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014331A1 (zh) * | 2016-07-22 | 2018-01-25 | 深圳市大富科技股份有限公司 | Usb金属管件加工设备及其上模板 |
| TWI654978B (zh) * | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| CA3107788A1 (en) * | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 ES ES21755253T patent/ES3039536T3/es active Active
- 2021-07-23 PH PH1/2023/550177A patent/PH12023550177A1/en unknown
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894B2/en active Active
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en not_active Ceased
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291B1/en active Active
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
-
2023
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 JO JOJO/P/2023/0018A patent/JOP20230018A1/ar unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537551A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| JP2023500032A5 (https=) | ||
| ME02474B (me) | Terapijski režimi | |
| UA51615C2 (uk) | Застосування сполуки, що має капа опіатагоністичну активність та спосіб лікування | |
| JP2021532193A5 (https=) | ||
| JP2019218379A5 (https=) | ||
| JP2020522560A5 (https=) | ||
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| JP2023548429A5 (https=) | ||
| JP2023535034A5 (https=) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2022177119A5 (https=) | ||
| JP2021512086A5 (https=) | ||
| JP2024528731A5 (https=) | ||
| JP2006528949A5 (https=) | ||
| IL300023A (en) | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound | |
| JP2023531930A5 (https=) | ||
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| CN104623671B (zh) | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 | |
| JP2022505184A5 (https=) | ||
| JP2022526495A5 (https=) | ||
| JP2022504435A5 (https=) | ||
| Upadhyay et al. | Gelucire: An alternative formulation technological tool for both sustained and fast release of drugs in treating diabetes mellitus type II disease |